Table 2.
Underlying targeting antigens of NSCLC and SCLC for CAR-T cell therapy in clinical trials.
| Clinical Trial | Cancer type | Targeting antigen | Sponsor | Estimated Enrollment | Phases | Status |
|---|---|---|---|---|---|---|
| NCT03054298 | NSCLC | Mesothelin | University of Pennsylvania | 18 | Phase 1 | Recruiting |
| NCT03330834 | NSCLC | PD-L1 | Sun Yat-sen University | 1 | Phase 1 | Terminated |
| NCT04489862 | NSCLC | αPD1, MSLN | Wuhan Union Hospital, China | 10 | Early Phase 1 | Recruiting |
| NCT03392064 | SCLC | delta-like protein 3 (DLL3) | Amgen | 6 | Phase 1 | Suspended |
| NCT03198546 | SCLC | GPC3 | Second Affiliated Hospital of Guangzhou Medical University | 30 | Phase 1 | Recruiting |
| NCT04348643 | Lung cancer | CEA | Chongqing Precision Biotech Co., Ltd | 40 | Phase1/2 | Recruiting |
| NCT04864821 | Lung cancer | CD276 (B7-H3) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 24 | Early Phase 1 | Not yet recruiting |
| NCT03740256 | Advanced HER2 Positive lung cancer | HER2 | Baylor College of Medicine | 45 | Phase 1 | Recruiting |
| NCT02706392 | NSCLC | ROR1 | Fred Hutchinson Cancer Research Center | 60 | Phase 1 | Recruiting |
| NCT03525782 | NSCLC | MUC1, PD-L1 | The First Affiliated Hospital of Guangdong Pharmaceutical University | 60 | Phase1/2 | Recruiting |
| NCT02587689 | NSCLC | MUC1 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 20 | Phase1/2 | Unknown |
| NCT04025216 | NSCLC | TnMUC1 | Tmunity Therapeutics | 112 | Phase 1 | Recruiting |
| NCT03198052 | Lung cancer | HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2, or B7-H3 | Second Affiliated Hospital of Guangzhou Medical University | 30 | Phase 1 | Recruiting |
| NCT03060343 | NSCLC | PD-L1, CD80/CD86 | Yu Fenglei | 10 | Phase 1 | Unknown |